Exosomes Articles & Analysis: Older
35 news found
It stabilizes the cellular fraction on nanocoated SmartBioSurface® slides for detecting rare cells like CTCs, while plasma is made available for the analysis of cfDNA, cfRNA/miRNA, proteins, metabolites, and exosomes. By processing fresh blood in EDTA tubes shortly after collection, See.d maintains sample integrity and clinical value. ...
Naturally, plant exosomes possess anti-inflammatory, antioxidant, and anti-aging properties. ...
CD Bioparticles provides comprehensive solutions to the limitations researchers might encounter in drug delivery and exosome research. Its products address challenges like restricted availability of control liposomes, complex lipid formulation, difficulties incorporating biomolecules onto liposomes, limited tracking methods for cellular interactions, and the overall ...
Exosomes are tiny vesicles secreted by cells, capable of transporting molecules from one cell to another. ...
CD Genomics' Exosomal RNA Sequencing service utilizes state-of-the-art next-generation sequencing (NGS) technologies, enabling high-throughput and cost-effective analysis of exosomal RNA samples. This advanced approach provides researchers with accurate and detailed insights into the complex exosomal transcriptome. Key features of CD Genomics' ...
The proprietary high-throughput technology is based on the interrogation of small noncoding RNAs (sncRNAs) extracted from urinary exosomes and was shown in clinical studies to detect and classify clinically significant prostate cancer with over 90% accuracy. ...
Tony is currently the CEO of Evox Therapeutics, an Oxford-based company developing exosome therapeutics, and has an extensive background in mRNA and more specifically LNPs through his roles at Moderna and Alnylam. ...
ByeTheRNA
Furthermore, epigenetic alterations, transporter protein abnormalities, non-coding RNA abnormalities, and exosomal modifications may also directly or indirectly contribute to the occurrence of drug resistance mechanisms. ...
EXO-NET is a pan-exosome capture that enables fast, precise and efficient isolation of exosomes for research applications. ...
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...
NEW YORK, July 13, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel™ Test assesses the ...
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards Lifesciences, Gilead and Genentech, Mr. ...
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. ...
Additionally, we continue to make progress with our engineered exosomes platform as we have invested internally in developing a scaled-up manufacturing paradigm that we believe will support clinical development as well as future potential partnering opportunities. ...
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. ...
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. ...
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics, announced today that its Phase 2, INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment option for hospitalized patients with advanced symptoms of COVID-19 met its primary objective of safety. ...
One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients Data Sets Stage for Pivotal Phase 3 HOPE-3 Clinical Trial Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the ...
” “Turning to our exosomes program, at this time, based on the current availability of vaccines for COVID-19, we have decided to hold off on further development of our exosome-mRNA vaccine. However, the power of exosomes as nature’s drug delivery system motivates us to becoming a leading exosomes company. ...
He has been a valued leader at large companies (3M) and emerging startups (Rion, StemoniX, Rebiotix) where he made significant contributions to the pioneering development of regenerative exosome and microbiome therapeutics, 3D organoids for drug discovery, and novel drug delivery technologies. ...